KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Account Payables (2017 - 2026)

Pacira BioSciences has reported Change in Account Payables over the past 12 years, most recently at -$936000.0 for Q1 2026.

  • For Q1 2026, Change in Account Payables fell 137.99% year-over-year to -$936000.0; the TTM value through Mar 2026 reached -$9.0 million, down 171.85%, while the annual FY2025 figure was -$5.6 million, 281.52% down from the prior year.
  • Change in Account Payables for Q1 2026 was -$936000.0 at Pacira BioSciences, up from -$2.9 million in the prior quarter.
  • Over five years, Change in Account Payables peaked at $9.7 million in Q2 2024 and troughed at -$12.0 million in Q3 2025.
  • A 5-year average of $219882.4 and a median of -$325000.0 in 2024 define the central range for Change in Account Payables.
  • Biggest five-year swings in Change in Account Payables: soared 932.94% in 2023 and later crashed 1985.87% in 2025.
  • Year by year, Change in Account Payables stood at $1.6 million in 2022, then plummeted by 167.38% to -$1.1 million in 2023, then soared by 69.68% to -$325000.0 in 2024, then tumbled by 801.23% to -$2.9 million in 2025, then surged by 68.04% to -$936000.0 in 2026.
  • Business Quant data shows Change in Account Payables for PCRX at -$936000.0 in Q1 2026, -$2.9 million in Q4 2025, and -$12.0 million in Q3 2025.